The Breast Cancer Epidemic: 10 Facts

Schneider, Andrew; Zainer, Christine M.; Kubat, Christopher Kevin; Mullen, Nancy K.; Windisch, A.

doi:10.1179/2050854914y.0000000027

Cited by 53 publications

(42 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A previous study identified that there has been a large increase in metastatic breast malignancy (to the bone, brain and lungs) in young women at the time of diagnosis (15). Therefore, a more effective and convenient screening method is required to reduce mortality and prolong overall survival.…”

Section: Discussionmentioning

confidence: 99%

“…Molecular diagnostic approaches are often non-invasive and may serve to improve the specificity and sensitivity of BC screening (15). It has been demonstrated that serological biomarkers are effective in the early diagnosis of various types of cancer, and are also cost-effective and convenient (19,29).…”

Section: Discussionmentioning

confidence: 99%

“…Oral contraceptive use may induce the proliferation of breast cells, therefore increasing the risk of breast development (23). It has also been determined that a window of susceptibility to breast cancer exists, in the time period between puberty onset and first full-term pregnancy (15). The process of pregnancy transforms pubescent breast tissue into fully mature tissue that contains type-4 lobules (24).…”

Section: Discussionmentioning

confidence: 99%

“…In addition, PLA2 and sPLA2 activities were associated with BC tumor stages. Other potential risk factors for BC development (15)(16)(17), including smoking, alcohol consumption, body-mass index (BMI) and age, were also assessed in the present study.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Plasma phospholipase A2 activity may serve as a novel diagnostic biomarker for the diagnosis of breast cancer

Zhao

Wang

et al. 2018

Oncol Lett

View full text Add to dashboard Cite

Abstract. Previous studies have indicated that phospholipase A2 (PLA2) may be associated with tumorigenesis in human tissues. The present study aimed to investigate the association between plasma PLA2 activity and the breast cancer (BC) status of patients. Increased plasma PLA2 activity was detected in patients with breast cancer when compared with healthy controls. Plasma samples were obtained from patients with BC (n=169), patients with benign disease (BD; n=80) and healthy controls (n=81). PLA2 activity was assessed using a quantitative fluorescent assay with selective inhibitors. It was demonstrated that increased PLA2 and secretory PLA2 (sPLA2) activity was associated with tumor stage, particularly in patients with late-stage disease. Additionally, smoking, alcohol consumption, body mass index (BMI) and age of patients did not have a significant effect on PLA2 activity. Analysis of receiver operating characteristic curves revealed that plasma PLA2 and sPLA2 activities were increased in BC patients compared with healthy controls. It was concluded that plasma PLA2 activity may serve as a biomarker for patients with BC.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Plasma phospholipase A2 activity may serve as a novel diagnostic biomarker for the diagnosis of breast cancer

Zhao

Wang

et al. 2018

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…Breast cancer cases cause about 370,000 related deaths in women each year even with all the significant progress in its diagnosis and treatment [22]. WHO [23] found out that breast cancer deaths in Nigeria reached 13,264 or 0.70% of total deaths and showed that Nigeria ranks 4 th in the world [11].…”

Section: Introductionmentioning

confidence: 99%

Some full blood count parameters among women of African descent with breast cancer in Sokoto, North Western Nigeria

Osaro¹,

Me²,

Michael³

et al. 2018

J Pregnancy Reprod

View full text Add to dashboard Cite

Breast cancer is the most common female malignancy both in Nigeria and globally. The aim of this case-control study was to determine the changes in some haematological parameters among breast cancer patients in Sokoto, Nigeria. The study included a total of 46 breast cancer subjects (mean age 42.91 ± 5.83 years) visiting the Specialist Hospital, in Sokoto, North Western Nigeria. A total of 46 apparently healthy age-matched women were monitored as control. Some haematological (packed cell volume, total white blood cell count and platelet count) were analyzed using the auto-haematology analyzer (Genesis, HA6000). Breast cancer staging was determined using the TNM classification. Data were analyzed using SPSS 22.0 statistical package. A p-value ≤0.05 was considered significant in all comparisons. The result indicated that patients with breast cancer had a lower mean packed cell volume (29.20 ± 0.50 %) compared to controls (36.20 ± 0.42 %) (p=0.000). The mean total white blood cell count of patients was also statistically lower among breast cancer patients (3.91 ± 0.19×10 9 /l) compared to controls (4.38 ± 0.13×10 9 /l) (p=0.045). There were no statistically significant differences in the mean value of platelet counts of breast cancer patients (197 ± 5.06×10 9 /l) and controls (207 ± 5.84×10 9 /l) (p=0.217). Newly diagnosed patients who were not on therapy had significantly lower mean values of PCV compared to controls (p<0.05). There were no statistically significant differences in the mean values of total white blood cell counts and platelets count of newly diagnosed patients that are not on therapy and controls (p>0.05). The mean PCV levels were significant lower as compared to controls (p<0.05) Patients that were on chemotherapy had significantly lower values of PCV, total white cell counts and platelets compared to patients who were not yet on any therapy (p <0.05). There were no statistically significant differences in the PCV, total white blood cell counts and platelets based on the different stages of breast cancer (p >0.05). Findings of this study have shown that breast cancer patients had a lower PCV and TWBC count compared to controls. Chemotherapy further exerts adverse effects on patients as seen with the significantly decreased values of haematological parameters on patients on therapy. Findings of this study also shows that breast cancer patients have low PCV and WBC count compared to controls. Haematological investigation should be taken as an essential tool in the investigation and management of breast cancer. Active breast cancer awareness campaign should be carried out on the need for early diagnosis. More research should be carried out to investigate the pattern of other haematological parameters in breast cancer disease.

show abstract

Perfluorinated alkylated substances serum concentration and breast cancer risk: Evidence from a nested case‐control study in the French E3N cohort

Mancini

Cano-Sancho

Gambaretti

et al. 2019

Intl Journal of Cancer

View full text Add to dashboard Cite

Endocrine‐disrupting chemicals are proposed to increase breast cancer (BC) incidence. Perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA), two perfluorinated alkylated substances (PFASs), are suspected to be ubiquitously present in the blood of human population worldwide. We investigated the associations between serum concentrations of these substances and BC risk. Etude Epidémiologique auprès de femmes de l'Education Nationale is a cohort of 98,995 French women born in 1925–1950 and followed up since 1990. We sampled 194 BC cases and 194 controls from women with available blood samples. Serum concentrations of PFASs were measured by liquid chromatography coupled to tandem mass spectrometry (LC–MS/MS). Adjusted conditional logistic regression models were used to estimate odds ratios (ORs) and 95% confidence intervals (CIs). All statistical tests were two sided. While PFASs concentrations were not associated with BC risk overall, we found positively linear associations between PFOS concentrations and the risk of ER+ (3rd quartile: OR = 2.22 [CI = 1.05–4.69]; 4th quartile: OR = 2.33 [CI = 1.11–4.90]); Ptrend = 0.04) and PR+ tumors (3rd quartile: OR = 2.47 [CI = 1.07–5.65]; 4th quartile: OR = 2.76 [CI = 1.21–6.30]; Ptrend = 0.02). When considering receptor‐negative tumors, only the 2nd quartile of PFOS was associated with risk (ER−: OR = 15.40 [CI = 1.84–129.19]; PR−: OR = 3.47 [CI = 1.29–9.15]). While there was no association between PFOA and receptor‐positive BC risk, the 2nd quartile of PFOA was positively associated with the risk of receptor‐negative tumors (ER−: OR = 7.73 [CI = 1.46–41.08]; PR−: OR = 3.44 [CI = 1.30–9.10]). PFAS circulating levels were differentially associated with BC risk. While PFOS concentration was linearly associated with receptor‐positive tumors, only low concentrations of PFOS and PFOA were associated with receptor‐negative tumors. Our findings highlight the importance of considering exposure to PFASs as a potential risk factor for BC.

show abstract

The Breast Cancer Epidemic: 10 Facts

Cited by 53 publications

References 73 publications

Plasma phospholipase A2 activity may serve as a novel diagnostic biomarker for the diagnosis of breast cancer

Plasma phospholipase A2 activity may serve as a novel diagnostic biomarker for the diagnosis of breast cancer

Some full blood count parameters among women of African descent with breast cancer in Sokoto, North Western Nigeria

Perfluorinated alkylated substances serum concentration and breast cancer risk: Evidence from a nested case‐control study in the French E3N cohort

Contact Info

Product

Resources

About